BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:27 PM
 | 
Apr 19, 2010
 |  BC Extra  |  Clinical News

Researchers report BATTLE data

Researchers from the M.D. Anderson Cancer Center reported data from the adaptive Phase II BATTLE trial evaluating biomarker-integrated approaches of targeted therapy in 255 stage IV non-small cell lung cancer (NSCLC) patients receiving Tarceva erlotinib, Zactima vandetanib, Nexavar sorafenib or Tarceva plus Targretin bexarotene. Each treatment had the highest disease control rate at eight weeks in certain biomarker subgroups. For example, Nexavar...

Read the full 308 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >